Commentary: The safety and efficacy of balloon-expandable vs. self-expanding trans-catheter aortic valve replacement in high-risk patients with severe symptomatic aortic stenosis
- PMID: 38193022
- PMCID: PMC10773742
- DOI: 10.3389/fcvm.2023.1295274
Commentary: The safety and efficacy of balloon-expandable vs. self-expanding trans-catheter aortic valve replacement in high-risk patients with severe symptomatic aortic stenosis
Keywords: TAVI; TAVR; aortic stenosis; balloon-expandable; randomized controlled trial; self-expanding.
Conflict of interest statement
MR reports receiving personal consulting fees from Abbott, Boston Scientific, Gore Medical and Medtronic outside of the submitted work. TB serves as a proctor for Medtronic and reports receiving personal consulting fees from Medtronic outside the submitted work. JP is an employee and shareholder of Medtronic.
Figures
Comment on
-
The safety and efficacy of balloon-expandable versus self-expanding trans-catheter aortic valve replacement in high-risk patients with severe symptomatic aortic stenosis.Front Cardiovasc Med. 2023 May 25;10:1130354. doi: 10.3389/fcvm.2023.1130354. eCollection 2023. Front Cardiovasc Med. 2023. PMID: 37351289 Free PMC article. Review.
References
-
- Senguttuvan NB, Bhatt H, Balakrishnan VK, Krishnamoorthy P, Goel S, Reddy PMK, et al. The safety and efficacy of balloon-expandable versus self-expanding trans-catheter aortic valve replacement in high-risk patients with severe symptomatic aortic stenosis. Front Cardiovasc Med. (2023) 10:1130354. 10.3389/fcvm.2023.1130354 - DOI - PMC - PubMed
Publication types
LinkOut - more resources
Full Text Sources
